Low Leverage / Strong Balance SheetA very low debt load provides durable financial flexibility: it reduces bankruptcy risk, preserves borrowing capacity for strategic moves, and allows management to fund commercialization or R&D without immediate refinancing pressure. This under‑leverage is a lasting structural strength.

Recovering Revenue TrendAn improving top line, with modest 2023 gains and stronger 2025 growth, indicates growing consumer adoption of ColdZyme and better distribution execution. Sustained revenue recovery supports operating leverage potential and creates runway to improve margins if costs are managed.

Diversified Go‑to‑market ModelA mixed model of direct sales plus partner licensing provides structural scalability: partners bring local market access and lower fixed costs, while direct channels retain margin and control. This reduces single‑channel risk and aids international expansion durability.

Bears Say

Persistent Operating LossesRecurrent, deep operating losses are a fundamental weakness: ongoing negative EBIT erodes equity, limits reinvestment, and means the business must rely on external capital to operate. Without sustainable profitability, long‑term independence and scale are constrained.

Chronic Negative Cash FlowPersistent cash burn indicates the core business does not self‑fund operations. This structural cash deficit forces reliance on equity or debt financing, increases dilution or leverage risk, and restricts the firm's ability to invest consistently in marketing, channels, or new products.

Eroding Equity And Negative ReturnsDeclining shareholder equity and negative ROE reflect that cumulative losses are shrinking the capital base. This reduces the balance sheet buffer against shocks, can lead to higher cost of capital, and may impair partner or lender confidence over the medium term.

ENZY FAQ

What was Enzymatica AB’s price range in the past 12 months?

Enzymatica AB lowest stock price was kr1.43 and its highest was kr5.45 in the past 12 months.

What is Enzymatica AB’s market cap?

Enzymatica AB’s market cap is kr449.06M.

When is Enzymatica AB’s upcoming earnings report date?

Enzymatica AB’s upcoming earnings report date is Apr 23, 2026 which is in 62 days.

How were Enzymatica AB’s earnings last quarter?

Enzymatica AB released its earnings results on Feb 18, 2026. The company reported -kr0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.05.

Is Enzymatica AB overvalued?

According to Wall Street analysts Enzymatica AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enzymatica AB pay dividends?

Enzymatica AB does not currently pay dividends.

What is Enzymatica AB’s EPS estimate?

Enzymatica AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enzymatica AB have?

Enzymatica AB has 242,735,100 shares outstanding.

What happened to Enzymatica AB’s price movement after its last earnings report?

Enzymatica AB reported an EPS of -kr0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.462%.

Which hedge fund is a major shareholder of Enzymatica AB?

Currently, no hedge funds are holding shares in SE:ENZY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enzymatica AB

Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme mouth spray, which prevents common cold and reduces the duration of illness. It also provides enzyme formulations. The company sells mouth spray under the ViruProtect brand in Denmark; STADAProtect brand in Germany; Psysiomer Stop Virus brand in France; and Zerinol Virus Defense brand in Italy. Enzymatica AB was incorporated in 2007 and is headquartered in Lund, Sweden.